Takeda takes $770M in write-downs after Alofisel flop, Exkivity withdrawal decision - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 27, 2023 at 4:27 PM in business No comments 55
Amgen will axe 350 former Horizon workers, post $27.8B buyout - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 25, 2023 at 6:41 PM in business No comments 24
ESMO: Jemperli appears to show survival edge over Keytruda - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 21, 2023 at 2:00 PM in business No comments 30
Padcev-Keytruda combo nearly doubles survival over SOC in trial - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 19, 2023 at 2:00 PM in business No comments 1
Merck's Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 17, 2023 at 10:24 PM in business No comments 19
Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 13, 2023 at 2:10 PM in business No comments 41
Study shows Novo's Ozempic, Wegovy pose risk of stomach problems - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 7, 2023 at 4:55 PM in news No comments 36
Apellis reports $74M in 3Q sales of Syfovre with demand up - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 6, 2023 at 3:22 PM in business No comments 27
In splitting from Novartis, Sandoz makes muted market debut - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 5, 2023 at 3:16 PM in business No comments 62
Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 4, 2023 at 1:55 PM in business No comments 57
Fierce 50: Breakthroughs honorees - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 3, 2023 at 8:00 AM in business No comments 10
Eli Lilly slapped with third FDA rejection in 2023, this time for eczema treatment lebrikizumab - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 3, 2023 at 3:06 PM in business No comments 38
Fierce 50: Innovation honorees - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 3, 2023 at 8:00 AM in business No comments 36
Merck's Lagevrio may have triggered new COVID variants: experts - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 26, 2023 at 1:35 PM in health No comments 32
After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy's Alfasigma - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 26, 2023 at 3:10 PM in business No comments 19
Novo Nordisk Foundation to set up cell therapy production 'hub' - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 21, 2023 at 1:30 PM in business No comments 61
Lilly pursues pharmacies, spas selling compounded Mounjaro - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 20, 2023 at 1:31 PM in business No comments 15
Novartis makes sculptures to shape knowledge of cancer symptoms, laying groundwork for Jakavi use - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 18, 2023 at 12:10 PM in health No comments 29
BMS aims for staggering 25 label expansions in the coming years - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 15, 2023 at 4:04 PM in business No comments 39
Sanofi, Ice-T partner on 'unique and edgy' flu vaccine campaign - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 13, 2023 at 12:15 PM in health No comments 56
AbbVie's Skyrizi deals heavy blow to J&J's Stelara in head-to-head Crohn's disease study - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 12, 2023 at 3:26 PM in business No comments 38
Data breach flagged at J&J's patient assistance program: IBM - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 6, 2023 at 10:59 PM in business No comments 40
Before key Tagrisso showdown, J&J notches Rybrevant trial win in large lung cancer area - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 6, 2023 at 3:35 PM in business No comments 18
Ovarian Cancer Research Alliance to boost screening for new Ovarian Cancer Awareness Month campaign - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 5, 2023 at 1:20 PM in health No comments 29
Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on September 5, 2023 at 3:17 PM in business No comments 2